Prevalence of other genetic alterations (RAS, TP53, CDKN2A, PREX2, and RASA2 mutations; CDKN2A and PTEN deletions, CCND1, MITF, and CDK4 amplifications) is higher in metastatic that in primary melanomas, most likely due to the expansion of cell subpopulations during tumor progression. Here, PTEN is linked to melanoma.